Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESRRB | O95718 | 14/20 | 1.00 |
| ▸ | ESRRA | P11474 | 14/20 | 1.00 |
| ▸ | ESR1 | P03372 | 2/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.41 |
| ▸ | DHODH | Q02127 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3936467 | 0.89 | ESRRB (1.00) | ESRRBESRRAESR1ESR2DHODH | |
| SCHEMBL3936583 | 0.86 | ESRRB (1.00) | ESRRBESRRAESR1ESR2DHODH | |
| SCHEMBL3922586 | 0.83 | ESRRB (1.00) | ESRRBESRRAESR1ESR2DHODH | |
| SCHEMBL3935889 | 0.83 | ESRRB (1.00) | ESRRBESRRA | |
| SCHEMBL3928250 | 0.82 | ESRRB (1.00) | ESRRBESRRAESR1ESR2DHODH | |
| SCHEMBL28125376 | 0.79 | ESRRB (0.66) | ESRRBESRRADHODH | |
| SCHEMBL3922805 | 0.79 | ESRRB (1.00) | ESRRBESRRADHODH | |
| SCHEMBL3930778 | 0.76 | ESRRB (1.00) | ESRRBESRRADHODH | |
| SCHEMBL14231578 | 0.76 | ESRRB (0.73) | ESRRBESRRAESR1ESR2DHODH | |
| SCHEMBL3922981 | 0.76 | ESRRB (1.00) | ESRRBESRRAESR1ESR2DHODH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009009417-A2 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF PREVENTING, TREATING, OR INHIBITING INFLAMMATORY DISEASES, DISORDERS, OR CONDITIONS OF THE SKIN, AND DISEASES, DISORDERS, OR CONDITIONS ASSOCIATED WITH COLLAGEN DEPLETION | WYETH (US) | 2009-01-15 | — | — | WO | claimed |
| US-20090010884-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF PREVENTING, TREATING, OR INHIBITING INFLAMMATORY DISEASES, DISORDERS, OR CONDITIONS OF THE SKIN, AND DISEASES, DISORDERS, OR CONDITIONS ASSOCIATED WITH COLLAGEN DEPLETION | WYETH (US) | 2009-01-08 | — | — | US | claimed |
| US-7354927-B2 | 6H-[1]benzopyrano[4,3-b]quinolines and their use as estrogenic agents | WYETH (US) | 2008-04-08 | — | — | US | claimed |
| EP-1789420-A2 | 6H-[1]BENZOPYRANO[4,3-b]QUINOLINES AND THEIR USE AS ESTROGENIC AGENTS | Wyeth, A Corporation of the State of Delaware (US) | 2007-05-30 | — | — | EP | claimed |
| WO-2006029146-A2 | 6H-[1]BENZOPYRANO[4,3-b]QUINOLINES AND THEIR USE AS ESTROGENIC AGENTS | WYETH (US) | 2006-03-16 | — | — | WO | claimed |
| US-20060052410-A1 | 6H-[1]benzopyrano[4,3-b]quinolines and their use as estrogenic agents | WYETH (US) | 2006-03-09 | — | — | US | claimed |
| WO-2009009417-A2 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF PREVENTING, TREATING, OR INHIBITING INFLAMMATORY DISEASES, DISORDERS, OR CONDITIONS OF THE SKIN, AND DISEASES, DISORDERS, OR CONDITIONS ASSOCIATED WITH COLLAGEN DEPLETION | WYETH (US) | 2009-01-15 | — | — | WO | disclosed |
| US-20090010884-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF PREVENTING, TREATING, OR INHIBITING INFLAMMATORY DISEASES, DISORDERS, OR CONDITIONS OF THE SKIN, AND DISEASES, DISORDERS, OR CONDITIONS ASSOCIATED WITH COLLAGEN DEPLETION | WYETH (US) | 2009-01-08 | — | — | US | disclosed |
| US-7354927-B2 | 6H-[1]benzopyrano[4,3-b]quinolines and their use as estrogenic agents | WYETH (US) | 2008-04-08 | — | — | US | disclosed |
| EP-1789420-A2 | 6H-[1]BENZOPYRANO[4,3-b]QUINOLINES AND THEIR USE AS ESTROGENIC AGENTS | Wyeth, A Corporation of the State of Delaware (US) | 2007-05-30 | — | — | EP | disclosed |
| WO-2006029146-A2 | 6H-[1]BENZOPYRANO[4,3-b]QUINOLINES AND THEIR USE AS ESTROGENIC AGENTS | WYETH (US) | 2006-03-16 | — | — | WO | disclosed |
| US-20060052410-A1 | 6H-[1]benzopyrano[4,3-b]quinolines and their use as estrogenic agents | WYETH (US) | 2006-03-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090010884-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF PREVENTING, TREATING, OR INHIBITING INFLAMMATORY DISEASES, DISORDERS, OR CONDITIONS OF THE SKIN, AND DISEASES, DISORDERS, OR CONDITIONS ASSOCIATED WITH COLLAGEN DEPLETION | COL2A1, COL1A1, COL14A1 | ESRRB 10/4885ESRRA 11/4885ESR1 4/4885 |
| US-20060052410-A1 | 6H-[1]benzopyrano[4,3-b]quinolines and their use as estrogenic agents | CYP19A1, ESR1, ESR2 | ESRRB 10/4885ESRRA 8/4885ESR1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.